雷竞技raybetAgilent Technologies，Inc。（NYSE：A）今天宣布已完成对下一代测序（NGS）基于基于的精度肿瘤学解决方案的开发和商业化的解决方案生物科学的收购。
解决方案生物科学补充并扩展了Agilent在基于NGS的癌症诊断中的能力，并为公司提供了创新雷竞技raybet技术，以进一步满足快速增长的精密医学市场的需求。分辨率生物科学的基于液体活检的诊断技术的增加增强了Agilent为生物制药和临床诊断客户提供的产品，并增加了公司诊断和基因组学业务中的增长机会。雷竞技raybet
"The Resolution Bioscience team and powerful technology are strategic and important additions to Agilent’s growing business in precision oncology solutions,” said Mike McMullen, Agilent president and CEO. “This also accelerates our work to more broadly deliver precision oncology testing for patients worldwide with NGS-based diagnostic kits. We’re excited to have Resolution Bioscience joining with us to expand our work in the fight against cancer."
前瞻性语句
该新闻稿包含1934年《证券交易法》中定义的前瞻性陈述，并受到其中创建的安全港口的约束。本文包含的前瞻性陈述包括但不限于有关收购能力和专业知识所带来的陈述，提供行业需求的能力，增长的加速和对收益的影响。这些前瞻性陈述涉及风险和不确定性，可能导致安捷伦的结果与管理层当前的期望有重大差异。雷竞技raybet这种风险和不确定性包括但不限于将分辨率生物科学的运营与安捷伦的运营相结合，保留关键员工，满足客户期望，实现合并企业的效率并实现预期税收优惠的能力。雷竞技raybet此外，Agilent在运营其运营方面面临的其他风险还包括通过雷竞技raybet业务周期成功执行的能力；实现并实现其降低成本目标并成功地使其成本结构的能力能够持续变化；持续的竞争，定价和严重的压力；我们的成本削减计划的风险将损害我们开发产品并保持竞争力并有效运作的能力；地缘政治不确定性和全球经济状况对我们的运营，我们的市场和开展业务的能力的影响；改善资产绩效以适应需求变化的能力； the ability of our supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended Jan. 31, 2021. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.